Navigation Links
Defending against chemical acts of terrorism
Date:6/8/2012

ions into the gene encoding a target enzyme, in this case PON1. The mutated versions of the gene are then put back into bacteria, which produce the enzymes for testing. The goal was to end up with enzymes capable of detoxifying G-type nerve agents before those nerve agents could reach their target and cause harm. Those that passed the initial test went on to further rounds of evolution and testing.

After four rounds of evolution, the researchers obtained PON1 variants that worked up to 340 times better than those produced previously. Overall, the researches reported that the PON1 variants showed 40- to 3,400-fold higher efficiency than the normal enzyme in metabolizing the three most toxic G-type nerve agents.

These new and improved PON1 enzymes have become promising candidates for use as preventive and postexposure treatments in the event of a terrorist attack.

"We hope that our enzymes would be able to act together with currently available drugs to improve survival rates following intoxication," Goldsmith said. More broadly, the findings show the power of laboratory evolution to completely reshape existing enzymes for a variety of uses.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Defending against chemical acts of terrorism
2. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
3. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
4. MU researchers identify key plant immune response in fight against bacteria
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
7. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
8. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
9. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
10. Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
11. Bio architecture lab technology converts seaweed to renewable fuels and chemicals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015 Oxford Finance LLC ... to life sciences and healthcare services companies, today announced ... loan agreement with Celula, Inc., a diagnostic testing company ... enabling better patient care and improved outcomes.  Proceeds of ... and expand the commercialization of its products in the ...
(Date:4/30/2015)... 30, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... of biosimilar therapeutics including high value and difficult ... its previously announced underwritten public offering of 6,750,000 ... offering price of $15.50 per share. This includes ... their option to purchase up to 750,000 additional ...
(Date:4/30/2015)... April 30, 2015 Available in ... http://www.lespausa.com , Fleur’s introduces ... combining the benefits of makeup, skin care and ... tinted cream is designed with specific complexion-correcting pigments ... even complexion and a healthy glow. Far more ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Sterlitech ... ultrafiltration membranes, the PX, PY, and PZ ... sheets, and disks. Designed to be ideal ... new membranes can fill critical process requirements where ... downstream processes. , “New regulations on industrial wastewater ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2
... Lixte,Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) today ... Bulletin Board under,the Symbol LIXT. Commenting on this ... "We believe that being a publicly traded company will,enable ... to us as,a private company. Having access to the ...
... of Cervical ... Cancer Risk, ... it has entered into an agreement to exclusively,license the Human Papillomavirus ... measurement of high-risk HPV types using,DNA-based detection. Quantovir is believed to ...
... MGCD0103,s Orphan Drug, Designation for the Treatment of ... BOULDER, Colo. and MONTREAL, Sept. 24 ,Pharmion Corporation ... MYG) today,announced that the European Medicines Agency (EMEA) ... deacetylase (HDAC),inhibitor, as an Orphan Medicinal Product for ...
Cached Biology Technology:Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 2Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 3Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT 4Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 2Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 3Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkin's Lymphoma 4
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... a mashup of monster movies, but palaeontologists have discovered evidence ... killing that took place 4 million years ago. ... careful, forensic-style analysis of bite marks on an otherwise well-preserved ... reconstructed the events that led to the death of the ...
... years of satellite data have found that the amount of ... the last three decades. Most of the increase has occurred ... increase in tropical regions. The new analysis shows, ... degrees a line that runs through central Texas in ...
... heart-healthy, essential omega-3 fatty acid is about to improve ... advance will move biotechnology onto the average consumer,s daily ... deliver positive environmental impacts and increase production to feed ... on Horizon , Recently, the U.S. Food and Drug ...
Cached Biology News:Jaws -- 4 million BC 2UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 2UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 3UV exposure has increased over the last 30 years, but stabilized since the mid-1990s 4New biotech advance to add heart healthy omega-3s to US diet 2
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Request Info...
Candida (IgG) -Ab EIA Sample Size: 5 l...
... The Oxidized LDL Competitive ELISA is ... in the sample competes with a fixed amount ... for the binding of the biotin- labeled specific ... 25 l The Oxidized LDL Competitive Enzyme-Linked ...
Biology Products: